Athira Pharma is a biopharmaceutical company focused on developing small molecules to slow neurodegradation and restore neuronal health. Their lead product candidate, ATH-1017, is in clinical trials for Alzheimer's and Parkinson's disease. They also have preclinical stage product candidates for peripheral nervous system indications and neuropsychiatric conditions. Formerly known as M3 Biotechnology, the company was incorporated in 2011 and is based in Bothell, Washington.